152915-83-8

Basic information

• Product Name: 6-(BENZYLOXY)-2-NAPHTHYLBORONIC ACID
• Synonyms: 6-BENZYLOXYNAPHTHALENE-2-BORONIC ACID;6-(BENZYLOXY)-2-NAPHTHYLBORONIC ACID;AKOS BRN-0518;6-Benzyloxy-2-naphthaleneboronic acid
• CAS NO: 152915-83-8
• Molecular Formula: C₁₇H₁₅BO₃
• Molecular Weight: 278.11
• Mol File: 152915-83-8.mol

Chemical Properties

• Boiling Point: 510.4 °C at 760 mmHg
• Flash Point: 262.5 °C
• Appearance: /
• Density: 1.24 g/cm³
• Vapor Pressure: 3.06E-11mmHg at 25°C
• Refractive Index: 1.655
• Storage Temp.: Room temperature.
• CAS DataBase Reference: 6-(BENZYLOXY)-2-NAPHTHYLBORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(BENZYLOXY)-2-NAPHTHYLBORONIC ACID(152915-83-8)
• EPA Substance Registry System: 6-(BENZYLOXY)-2-NAPHTHYLBORONIC ACID(152915-83-8)

Safety Data

• Hazard Codes: Xi:Irritant
• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S37/39:Wear suitable g
• Hazardous Substances Data: 152915-83-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
6-(Benzyloxy)-2-naphthylboronic acid is used as a reagent in organic synthesis for the formation of stable covalent bonds. Its unique structure allows for versatile applications in the synthesis of various organic compounds.
Used in Pharmaceutical Industry:
6-(Benzyloxy)-2-naphthylboronic acid is used as an intermediate in the synthesis of pharmaceuticals. Its ability to form stable covalent bonds makes it a valuable component in the development of new drugs and medicinal compounds.
Used in Agrochemicals:
6-(Benzyloxy)-2-naphthylboronic acid is used as a building block in the production of agrochemicals. Its stable covalent bonding properties contribute to the development of effective and safe agricultural products.
Used in Coupling Reactions:
6-(Benzyloxy)-2-naphthylboronic acid is used as a coupling agent in various chemical reactions. Its reactivity and stability make it a preferred choice for facilitating the formation of new chemical bonds in complex molecules.

InChI:InChI=1/C17H15BO3/c19-18(20)16-8-6-15-11-17(9-7-14(15)10-16)21-12-13-4-2-1-3-5-13/h1-11,19-20H,12H2

Upstream product

• 15231-91-1 6-bromo-naphthalen-2-ol 
• 2234-45-9 6-benzyloxy-2-bromonaphthalene 
• 100-39-0 benzyl bromide 
• 5419-55-6 Triisopropyl borate 

Downstream Products

• 244103-66-0 (E)-3-[2-(6-Benzyloxy-naphthalen-2-ylmethyl)-phenyl]-acrylic acid 

Relevant articles and documents

CuCF3: A [18F]trifluoromethylating agent for arylboronic acids and aryl iodides

Positron emission tomography has emerged as the leading method for medical imaging with fluorine-18 as the most widely used radioactive isotope. Here we report a semi-automated method for the preparation of valuable [ 18F]trifluoromethylcopper, as well as its use for the radiosynthesis of [18F]trifluoromethylarenes and heteroarenes. Mild conditions of [18F]trifluoromethylation make this method particularly useful for the radiosynthesis of pharmacologically relevant [18F] trifluoromethylarenes and heteroarenes. 18F Radiochemistry: A semi-automated method for the fast preparation of radiolabelled (trifluoromethyl)copper is reported (see scheme), thus making [ 18F]CuCF3 almost as accessible as [18F]fluoride itself for the preparation of radiolabelled trifluoromethylated probes. It can be used for the preparation of radiolabelled trifluoromethylarenes from arylboronic acids and aryliodides. This methodology is clean, efficient and consistent with the specific requirements of radiochemistry.

Comparison between two classes of selective EP3 antagonists and their biological activities

Two different series of very potent and selective EP3 antagonists have been reported: a novel series of ortho-substituted cinnamic acids [Belley, M., Gallant, M., Roy, B., Houde, K., Lachance, N., Labelle, M., Trimble, L., Chauret, N., Li, C.,

Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment

Compounds of formula I: as well as pharmaceutically acceptable salts, hydrates and esters thereof, are disclosed. The compounds are useful for treating or preventing prostaglandin mediated diseases. Pharmaceutical compositions containing such compounds and methods of treatment are also included.